Drug updated on 11/16/2023
| Dosage Form | Capsule (oral; 123 mg) |
| Drug Class | Alpha-galactosidase A pharmacological chaperones |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Galafold (migalastat) Prescribing Information. | 2021 | Amicus Therapeutics, Cranbury, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical review report: migalastat (Galafold). | 2018 | CADTH |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. | 2023 | Frontiers in Medicine |
| The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts. | 2020 | Orphanet Journal of Rare Diseases |
| Canadian Fabry disease treatment guidelines 2018. | 2019 | Garrod Association |